HealthJoy Partners With CareValidate to Transform GLP-1 Access and Affordability
Collaboration offers up to 50% savings on GLP-1 medications while protecting employer pharmacy spend
CHICAGO, ILLINOIS / ACCESS Newswire / April 8, 2025 / HealthJoy, a leader in healthcare navigation, today announced a landmark partnership with CareValidate to enhance access and affordability of popular GLP-1 receptor agonists. This strategic collaboration delivers substantial discounts to members while safeguarding employer pharmacy spend.
The partnership comes at a critical time as demand for GLP-1 medications like Ozempic®, Wegovy®, and Mounjaro® continues to surge. Weight loss medications are the most requested class of medications by HealthJoy members.
With 2-3% of U.S. adults currently taking these medications and up to 20% expressing interest, employers face increasing pressure to provide access despite monthly retail costs of $900-$1,300.
Through this collaboration, HealthJoy offers:
'What makes GLP-1s so compelling is their ability to address multiple drivers of cardiometabolic disease in a single therapy. This is why they have already become a foundational tool in how we approach metabolic health at scale,' said Jiten Chhabra, Chief Medical Officer at CareValidate. 'Now we can move upstream and tackle the root causes of cardiometabolic disease instead of just managing their complications, which has been the industry approach for far too long. This is truly a game-changer for population health and long-term cost savings for employers.'
In addition to this partnership, HealthJoy is making technology enhancements to help employers control spend. By integrating with a leading pharmacy coupon service, HealthJoy identifies cost-saving opportunities - up to 80% off retail prices - and delivers personalized recommendations directly to members within the app.
'As pharmacy costs continue to dominate benefits discussions, employers need innovative solutions that balance access with affordability,' said Justin Holland, CEO and Co-Founder of HealthJoy. 'Our approach transforms how organizations can support employee health needs while strategically managing their pharmacy spend.'
These innovations arrive as employers begin to plan their 2026 benefits strategy and seek solutions that improve medication access without complex plan redesigns.
ABOUT HEALTHJOY
HealthJoy is transforming the healthcare benefits experience by combining intuitive technology with human guidance to drive smarter care decisions. The company's proactive approach reduces claims costs, leading to a 21% decrease in healthcare spend and measurable savings for employers. With 80% of members following HealthJoy's care recommendations, organizations benefit from healthier teams, improved ROI, and more effective benefits strategies. Following its Series D funding, HealthJoy now serves over 1 million members and dependents across 1,800 employer clients. Backed by 14 strategic investors, the company remains committed to simplifying healthcare navigation and lowering costs. For more information, visit healthjoy.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Circus SE Appoints Former Helsing Top-Executive Sasha Borovik as General Counsel
Borovik, a Harvard Law graduate, brings 20+ years of legal leadership across AI, tech, and defense, including as Director of Legal Affairs at Microsoft and key legal architect behind defense AI leader Helsing's $5Bn scale-up. He brings deep expertise in global negotiations and IP strategy across commercial and defense sectors - working with customers such as NATO, the UN, and Ukrainian forces. Joins as Circus' first core defense executive to accelerate international growth and legal strategy following the CA-M launch as its first autonomous solution for the defense sector and the CA-1 serial production. MUNICH, June 11, 2025--(BUSINESS WIRE)--Circus SE (XETRA: CA1), a global leader in AI software and robotics for the food service industry, announces the appointment of Sasha Borovik as General Counsel effective June 11, 2025. A graduate of Harvard Law School with over two decades of global legal and commercial leadership, Borovik has negotiated complex technology, defense, and AI transactions on behalf of major corporations and institutions. His track record spans work with NATO-aligned governments, the UN, and AI leaders shaping next-generation defense infrastructure. At Helsing, Europe's leading defense AI company, Borovik played a pivotal role as General Counsel and Director of Compliance - not only building the legal function, but also leading the structuring and execution of multiple capital rounds totaling over $800 million to date. His legal leadership was instrumental in navigating dual-use technology regulation, defense contracting, and IP protection in one of Europe's most strategically important AI ventures. Prior to Helsing, Borovik served as Senior Director and Lead Counsel for EMEA at Akamai Technologies (Nasdaq: AKAM), and Director of Legal Affairs at Microsoft (Nasdaq: MSFT) as a head lawyer for the public sector, where he supported global expansion, strategic partnerships, and high-value commercial transactions across regulated markets. Borovik's appointment comes as Circus prepares for the launch of its CA-M defense product line, the world's first autonomous meal supply system designed for defense and critical infrastructure, and ramps up serial production of its core CA-1 system. As the company's first core defense executive, he will play a critical role in shaping commercial agreements, institutional partnerships, and regulatory strategy across dual-use domains. "Joining Circus is an opportunity to shape the strategic and legal backbone of a company that's redefining autonomy at scale," said Sasha Borovik. "With the CA-M and a growing international footprint, Circus is stepping into domains where legal rigor and regulatory foresight are not just an asset - they're mission-critical." "Sasha brings a rare combination of legal excellence, deal-making experience, and deep domain knowledge in defense and AI," said Nikolas Bullwinkel, CEO and Founder of Circus SE. "As we expand negotiations with multiple NATO-aligned forces and scale internationally, his leadership will be instrumental in building robust, long-term partnerships." Borovik holds law degrees from Harvard Law School and Charles University in Prague. He speaks seven languages and is admitted to the bar in both the European Union and the state of New York. About Circus SE Circus SE (XETRA: CA1) is a global AI and robotics company developing autonomous systems for food supply in both civilian and defense sectors. Its flagship robot, the patented CA-1, is the world's first fully autonomous food production robot, now in serial production. Powered by proprietary embodied AI, Circus delivers industrial-scale, high-reliability meal output with minimal human input. Headquartered in Munich, the company is building the global infrastructure for autonomous food supply — on a mission to fuel humanity. Language: English Company: Circus SE Hongkongstrasse 6 20457 Hamburg Germany E-mail: ir@ Internet: ISIN: DE000A2YN355 WKN: A2YN35 Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate Exchange View source version on Contacts Circus SEpress@
Business Wire
2 hours ago
- Business Wire
Circus SE Appoints Former Helsing Top-Executive Sasha Borovik as General Counsel
MUNICH--(BUSINESS WIRE)--Circus SE (XETRA: CA1), a global leader in AI software and robotics for the food service industry, announces the appointment of Sasha Borovik as General Counsel effective June 11, 2025. A graduate of Harvard Law School with over two decades of global legal and commercial leadership, Borovik has negotiated complex technology, defense, and AI transactions on behalf of major corporations and institutions. His track record spans work with NATO-aligned governments, the UN, and AI leaders shaping next-generation defense infrastructure. At Helsing, Europe's leading defense AI company, Borovik played a pivotal role as General Counsel and Director of Compliance - not only building the legal function, but also leading the structuring and execution of multiple capital rounds totaling over $800 million to date. His legal leadership was instrumental in navigating dual-use technology regulation, defense contracting, and IP protection in one of Europe's most strategically important AI ventures. Prior to Helsing, Borovik served as Senior Director and Lead Counsel for EMEA at Akamai Technologies (Nasdaq: AKAM), and Director of Legal Affairs at Microsoft (Nasdaq: MSFT) as a head lawyer for the public sector, where he supported global expansion, strategic partnerships, and high-value commercial transactions across regulated markets. Borovik's appointment comes as Circus prepares for the launch of its CA-M defense product line, the world's first autonomous meal supply system designed for defense and critical infrastructure, and ramps up serial production of its core CA-1 system. As the company's first core defense executive, he will play a critical role in shaping commercial agreements, institutional partnerships, and regulatory strategy across dual-use domains. 'Joining Circus is an opportunity to shape the strategic and legal backbone of a company that's redefining autonomy at scale,' said Sasha Borovik. 'With the CA-M and a growing international footprint, Circus is stepping into domains where legal rigor and regulatory foresight are not just an asset - they're mission-critical.' 'Sasha brings a rare combination of legal excellence, deal-making experience, and deep domain knowledge in defense and AI,' said Nikolas Bullwinkel, CEO and Founder of Circus SE. 'As we expand negotiations with multiple NATO-aligned forces and scale internationally, his leadership will be instrumental in building robust, long-term partnerships.' Borovik holds law degrees from Harvard Law School and Charles University in Prague. He speaks seven languages and is admitted to the bar in both the European Union and the state of New York. About Circus SE Circus SE (XETRA: CA1) is a global AI and robotics company developing autonomous systems for food supply in both civilian and defense sectors. Its flagship robot, the patented CA-1, is the world's first fully autonomous food production robot, now in serial production. Powered by proprietary embodied AI, Circus delivers industrial-scale, high-reliability meal output with minimal human input. Headquartered in Munich, the company is building the global infrastructure for autonomous food supply — on a mission to fuel humanity.
Yahoo
2 hours ago
- Yahoo
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT™ platform and proven Flow Electroporation® technology, widely recognized for its efficient and scalable transfection capabilities, utilized in over 19 active clinical and commercial programs, with Ori's innovative next-generation cell therapy manufacturing platform, IRO® (ee-RO). The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. As a key component of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation. MaxCyte's technology offers unparalleled flexibility and efficiency in transfecting cells at clinical scale, seamlessly integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling, customizable mixing, and the OriConnect® tubeless sterile connection system, enhancing cell culture efficiency and scalability. Together, these complementary technologies provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently. Maher Masoud, President and CEO of MaxCyte, commented, 'We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes. This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.''Our partnership with MaxCyte is another example of Ori's dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing,' said Jason C. Foster, CEO of Ori Biotech. 'By integrating modular, best-of-breed technologies, we're raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.' Through their shared commitment to innovation and industry collaboration, MaxCyte and Ori Biotech are enabling developers of advanced therapies to adopt integrated, best-of-breed solutions, accelerating the path from research to commercialization and making next-generation treatments more accessible to patients globally. About MaxCyte At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at and follow us on X and LinkedIn. About Ori Biotech Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori's next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products' clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics. For news and updates, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits, outcomes, and impact of the collaboration between MaxCyte and Ori Biotech; the potential for improving clinical success and commercial viability through new manufacturing standards; and the intention to accelerate development timelines, increase access to next-generation cell therapies, and deliver transformative treatments to patients globally. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which MaxCyte operates, as well as management's current beliefs and assumptions. Words such as 'aims,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'should,' 'continue,' and variations of such words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict and are often beyond the control of the companies involved. Actual outcomes and results may differ materially from those expressed or implied in these forward-looking statements due to various factors, including changes in market conditions, technological advancements, regulatory developments, and the success of ongoing research and evaluation efforts. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended May 8, 2025. These documents are available through the Investor Menu, Financials section, under 'SEC Filings' on the Investors page of our website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, MaxCyte does not undertake any obligation to update or revise any forward-looking statements to reflect new information, events, or circumstances after the date of this release. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@ Oak Street CommunicationsKristen Whitekristen@ Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@ Ori Biotech Contact: Debby Betzmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
